Awesome news!! I have been approved for AMX0035!!! This is the latest drug , developed here in Boston, to fight ALS.

Dit is allemaal manipulatie van de beeldvorming. We zagen dit bijvoorbeeld bij de motie over AMX0035.

Programming Note: On Monday afternoon, BiotechTV will speak with the Co-CEOs of Amylyx about today's CHMP decision and what it means for ALS patients, AMX0035, and the company.

$AMLX
- pipeline below
-Book Value Per Share: 6.40
-Total Cash Per Share: 5.48
-Net Cash/Share 5.42
-Next catalyst: AMX0035 - (HELIOS)
Wolfram Syndrome: Phase 2 first patient dosed April 13, 2023. Phase 2 enrollment completed, noted February 8, 2024.Phase 2 data due in 2H 2024.

【ALS世界ニュース】🌍
アミリックス社のALS治療薬AMX0035 (米国製品名レリブリオ）市場から撤退

以前お知らせしました、アメリカ🇺🇸のALS治療薬レリブリオのフェーズ３トライアルの失敗の件のアップデートニュースになります。

p-als.com/news/world-new…

#ALS

FDA Biologics Waitttt you’re telling me AMX0035 (Relyvrio) doesn’t work!? I’m shocked 😮 #saracsm #Fails #ALS

You know what did show significant effects in some patients and needs to be made accessible and investigated further!?….yup #NUROWN

#FDA get your act together already.

Biotech News 7/12 @ Close📰

$RXRX 115% Collab w/ NVIDIA
$AVRO 46% Halting program development
$CVKD 29% $7.5M Private Placement
$LPTX 6% DeFianCe Part B initiation
$AMLX 3% AMX0035 webcast July 26
$AZN 2% Enhertu approved in China
$BGNE 2% sNDA accepted
$DARE 1% Upcoming…

Amylyx Therapeutics ile buluşuyoruz. 1 Mart Cuma saat 13:00 İstanbul
#AMYLYX #als #amx0035 #Relyvrio #Albrioza

We previously performed a study demonstrating AMX0035 improves in Wolfram Syndrome patient iPSC-derived islets with Fumi Urano MD PhD - Wolfram Doc. @amylyxpharma just announced interim clinical trial data with AMX0035 showing improved diabetes and vision! Congratulations! amylyx.com/news/amylyx-ph…

The world of trials. A sodium phenylbutyrate and taurursodiol combination (PB&TURSO, AMX0035) met the primary endpoint in the #ALS Phase 2 CENTAUR trial, not in the Phase 3 PHOENIX trial. The future? Find subgroups within to like. The hypothesis? it is fine, thank you. #AANAM

Biotech News 7/12 @ Mid-day📰

$RXRX 64% Collab w/ NVIDIA
$AVRO 42% Halting program development
$LPTX 4% DeFianCe Part B initiation
$AZN 2% Enhertu approved in China
$AMLX 2% AMX0035 webcast July 26
$BGNE 2% sNDA accepted
$DARE 1% Upcoming presentation

Check out the image for…

The #time is #now for the EU Medicines Agency
to grant conditional approval of #AMX0035 for #ALS #MND in #Europe . Make it happen #EMA #CHMP !

#Handicap Les patients français atteints de la maladie de #Charcot sont dorénavant éligibles à la prise de l’AMX0035. Un nouveau traitement issu de la combinaison de deux molécules qui pourrait accroître leur espérance de vie. Une victoire pour ARSLA
faire-face.fr/2023/11/02/sla…

The time is #now for the EU Medicines Agency to grant conditional approval @Amylyx’s #AMX0035 for #ALS #MND in #Europe . Make it happen #EMA #CHMP !

$AMLX announced topline results from the Phase 3 PHOENIX trial of AMX0035 in people living with amyotrophic lateral sclerosis (ALS). PHOENIX did not meet its primary endpoint of reaching statistical significance as measured by change from baseline in the Revised Amyotrophic…

🇨🇵 Maladie de #Charcot ou #SLA : le traitement #AMX0035 arrive en France.

Ce traitement issu de la combinaison de 2 molécules ne dispose pourtant pas (encore) d’autorisation de mise sur le marché en France mais certains patients sont éligibles.

ARSLA

faire-face.fr/2023/11/02/sla…

The #time is #now for the EU Medicines Agency to grant conditional approval of #AMX0035 for #ALS #MND in #Europe . Make it happen #EMA #CHMP !

The time is #now for the EU Medicines Agency to grant conditional approval @Amylyx’s #AMX0035 for #ALS #MND in #Europe . Make it happen #EMA #CHMP !

BREAKING:
EUpALS Industry Partner Amylyx regrets to inform the #ALS / #MND community that their Phase 3 PHOENIX trial with AMX0035 did not meet the primary and secondary endpoints. Read the press release. Despite this negative result, Amylyx stays committed in ALSMND.

$AMLX
Amylyx Pharmaceuticals Announces Publication of Data Showing the Effect of AMX0035 on Plasma Neuroin... - AMLX • BioPharmCatalyst biopharmcatalyst.com/company/AMLX/n…